Personalized Radiotherapy for Biochemical Recurrence of Prostate Cancer After Prostatectomy.
ConditionProstate Cancer
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexMale
Age18+
SponsorLund University Hospital
About this trial
A randomized phase III trial to study the effect of adding lymph node irradiation in patients with poor prostate-specific antigen (PSA) response during salvage radiotherapy for biochemical recurrence (0.15 ≤ PSA \<0.70 ng/ml) after prostatectomy.
Eligibility criteria
Qualifiers
Life expectancy > 10 years
Age ≥18 years.
World Health Organization (WHO) performance status 0-1.
Estimated life expectancy >10 years.
Disqualifiers
Metastases (regional lymph nodes or distant)* diagnosed with imaging.
Prior or ongoing hormonal therapy (antiandrogens or gonadotropin releasing hormone).
Prior radiotherapy to the pelvis.
Prior malignancy other than prostate cancer and basalioma in the past five years.
Trial design
Treatments tested in this trial
- Radiation to the prostate bed with or without addition of radiation of lymph node irradiation.
Treatment groups
374 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov